Research progress of chronic obstructive pulmonary disease complicated with pulmonary tuberculosis

doi:10.19983/j.issn.2096-8493.20220013

Abstract

Abstract:

The number of patients with chronic obstructive pulmonary disease (COPD) complicated with pulmonary tuberculosis is increasing. The coexistence and interaction of the two diseases bring difficulties to the diagnosis and treatment of the disease, increasing the disease burden and the risk of death. This article reviewed the risk factors of COPD combined with pulmonary tuberculosis, the clinical characteristics of the combination of the two diseases, the differential diagnosis between COPD and pulmonary tuberculosis related obstructive pulmonary disease, and the prevention and treatment of chronic obstructive pulmonary disease combined with pulmonary tuberculosis.

Key words: Pulmonary disease, chronic obstructive, Tuberculosis, pulmonary, Comorbidity, Disease attributes, Review literature as topic

CLC Number:

R563
R521

Zhou Yinan, Zhu Huili. Research progress of chronic obstructive pulmonary disease complicated with pulmonary tuberculosis[J]. Journal of Tuberculosis and Lung Disease , 2022, 3(4): 338-342. doi: 10.19983/j.issn.2096-8493.20220013

References 44

[1]	Global Initiative for Chronic Obstructive Lung Disease.2022 GOLD Reports.Tinton Falls:Global Initiative for Chronic Obstructive Lung Disease,2022.
[2]	Burney P, Jarvis D, Perez-Padilla R. The global burden of chronic respiratory disease in adults. Int J Tuberc Lung Dis, 2015, 19(1):10-20. doi: 10.5588/ijtld.14.0446. doi: 10.5588/ijtld.14.0446 pmid: 25519785
[3]	Weng C, Xu J, Yang L, et al. Prevalence and risk factors of chronic obstructive pulmonary disease in China(the China Pulmonary Health[CPH] study):a national cross-sectional study. Lancet, 2018, 391(10131):1706-1717. doi: 10.1016/S0140-6736(18)30841-9. doi: 10.1016/S0140-6736(18)30841-9 URL
[4]	World Health Organization.Global tuberculosis report 2021.Geneva:World Health Organization, 2021.
[5]	O’Toole RF, Shukla SD, Walters EH. TB meets COPD: An emerging global co-morbidity in human lung disease. Tuberculosis(Edinb),2015, 95(6):659-663. doi: 10.1016/j.tube.2015.08.005. doi: 10.1016/j.tube.2015.08.005
[6]	Chakrabarti B, Calverley PM, DaviesPD. Tuberculosis and its incidence, special nature, and relationship with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis, 2007, 2(3): 263-272.
[7]	Inghammar M, Ekbom A, Engström G, et al. COPD and the risk of tuberculosis—a population-based cohort study. PLoSOne, 2010, 5(4):e10138. doi: 10.1371/journal.pone.0010138. doi: 10.1371/journal.pone.0010138
[8]	Salvi SS, Barnes PJ. Chronic obstructive pulmonary disease in non-smokers. Lancet, 2009, 374(9691):733-743. doi: 10.1016/S0140-6736(09)61303-9. doi: 10.1016/S0140-6736(09)61303-9 URL
[9]	Rhee CK, Chau NQ, Yunus F, et al. Management of COPD in Asia: A position statement of the Asian Pacific Society of Respirology. Respirology, 2019, 24(10):1018-1025. doi: 10.1111/resp.13633. doi: 10.1111/resp.13633 URL
[10]	Davies PD, Yew WW, Ganguly D, et al. Smoking and tuberculosis: the epidemiological association and immunopathogenesis. Trans R Soc Trop Med Hyg, 2006, 100(4):291-298. doi: 10.1016/j.trstmh.2005.06.034. doi: 10.1016/j.trstmh.2005.06.034 URL
[11]	Jayes L, Haslam PL, Gratziou CG, et al. SmokeHaz: Systema-tic Reviews and Meta-analyses of the Effects of Smoking on Respiratory Health. Chest, 2016, 150(1):164-179. doi: 10.1016/j.chest.2016.03.060. doi: 10.1016/j.chest.2016.03.060 pmid: 27102185
[12]	O’Leary SM, Coleman MM, ChewWM. Cigarette smoking impairs human pulmonary immunity to Mycobacterium tuberculosis. Am J Respir Crit Care Med, 2014, 190(12): 1430-1436. doi: 10.1164/rccm.201407-1385OC. doi: 10.1164/rccm.201407-1385OC URL
[13]	Nakao M, Muramatsu H, ArakawaS, et al. Immunonutritional status and pulmonary cavitation in patients with tuberculosis: A revisit with an assessment of neutrophil/lymphocyte ratio. Respir Investig, 2019, 57(1):60-66. doi: 10.1016/j.resinv.2018.08.007. doi: 10.1016/j.resinv.2018.08.007 URL
[14]	Jones BJ, Johnston V, Appuhamy RD, et al.The epidemiology of tuberculosis in the Australia Capital Territory, 2006—2015. Commun Dis Intell Q Rep, 2017, 41(3):E231-E240.
[15]	侯婧, 张妍蓓. 536例老年肺结核患者血清白蛋白、血红蛋白等相关指标分析. 实用医学杂志, 2016, 32(1):134-136.
[16]	全国第五次结核病流行病学抽样调查技术指导组、全国第五次结核病流行病学抽样调查办公室. 2010年全国第五次结核病流行病学抽样调查报告. 中国防痨杂志, 2012, 34(8):485-505.
[17]	Turnbull ER, Drobniewski F. Vitamin D supplementation: a comprehensive review on supplementation for tuberculosis prophylaxis. Expert Rev Respir Med, 2015, 9(3): 269-275. doi: 10.1586/17476348.2015.1042458. doi: 10.1586/17476348.2015.1042458 URL
[18]	Karbalaei M, Ghazvini K, Keikha M, et al. Clinical efficacy of vitamin D supplementation on pulmonary TB patients:The evidence of clinical trials. J Clin Tuberc Other Mycobact Dis, 2020, 20:100174. doi: 10.1016/j.jctube.2020.100174. doi: 10.1016/j.jctube.2020.100174
[19]	Wu HX, Xiong XF, Zhu M, et al. Effects of vitamin D supplementation on the outcomes of patients with pulmonary tuberculosis: a systematic review and meta-analysis. BMC Pulm Med, 2018, 18(1):108. doi: 10.1186/s12890-018-0677-6. doi: 10.1186/s12890-018-0677-6 URL
[20]	Hsu IL, Lu CL, Li CC, et al. Population-based cohort study suggesting a significantly increased risk of developing chronic obstructive pulmonary disease in people with type 2 diabetes mellitus. Diabetes Res Clin Pract, 2018, 138:66-74. doi: 10.1016/j.diabres.2018.01.037. doi: 10.1016/j.diabres.2018.01.037 URL
[21]	Gläser S, Krüger S, Merkel M, et al. Chronic obstructive pulmonary disease and diabetes mellitus: a systematic review of the literature. Respiration, 2015, 89(3):253-264. doi: 10.1159/000369863. doi: 10.1159/000369863 pmid: 25677307
[22]	Jiménez-Corona ME, Cruz-Hervert LP, García-García L, et al. Association of diabetes and tuberculosis: impact ontreatment and post-treatment outcomes. Thorax, 2013, 68(3):214-220. doi: 10.1136/thoraxjnl-2012-201756. doi: 10.1136/thoraxjnl-2012-201756 pmid: 23250998
[23]	Riza AL, Pearson F, Ugarte-Gil C, et al. Clinical management of concurrent diabetes and tuberculosis and the implications for patient services. Lancet Diabetes Endocrinol, 2014, 2(9):740-753. doi: 10.1016/S2213-8587(14)70110-X. doi: 10.1016/S2213-8587(14)70110-X URL
[24]	Pérez-Navarro LM, Fuentes-Domínguez FJ, Zenteno-Cuevas R. Type 2 diabetes mellitus and its influence in the development of multidrug resistance tuberculosis in patients from southeastern Mexico. J Diabetes Complications, 2015, 29(1):77-82. doi: 10.1016/j.jdiacomp.2014.09.007. doi: 10.1016/j.jdiacomp.2014.09.007 URL
[25]	Kim JH, Park JS, Kim KH, et al. Inhaled corticosteroid is associated with an increased risk of TB in patients with COPD. Chest, 2013, 143(4):1018-1024. doi: 10.1378/chest.12-1225. doi: 10.1378/chest.12-1225 URL
[26]	Aktogˇu S, Yorgancioglu A, CirakK,et al. Clinical spectrum of pulmonary and pleural tuberculosis: a report of 5,480 cases. Eur Respir J, 1996, 9(10):2031-2035. doi: 10.1183/09031936.96.09102031. doi: 10.1183/09031936.96.09102031 URL
[27]	Lee CH, Lee MC, Shu CC, et al. Risk factors for pulmonary tuberculosis in patients with chronic obstructive airway disease in Taiwan:a nationwide cohort study. BMC Infect Dis, 2013, 13:194-199. doi: 10.1186/1471-2334-13-194. doi: 10.1186/1471-2334-13-194 URL
[28]	Jin J, Li S, Yu W, et al. Emphysema and bronchiectasis in COPD patients with previous pulmonary tuberculosis: computed tomography features and clinical implications. Int J Chron Obstruct PulmonDis, 2018, 13: 375-384. doi: 10.2147/COPD.S152447. doi: 10.2147/COPD.S152447
[29]	Park HJ, Byun MK, Kim HJ, et al. History of pulmonary tuberculosis affects the severity and clinical outcomes of COPD. Respirology, 2018, 23(1):100-106. doi: 10.1111/resp.13147. doi: 10.1111/resp.13147
[30]	Kadowaki T, Yano S, Wakabayashi K, et al. Pulmonary tuberculosis with atypical radiological findings in a patient with chronic obstructive pulmonary disease. Kekkaku, 2011, 86(8):763-766.
[31]	Han S, Yoon SH, Goo JM, et al. Radiological features and progression of incipient active pulmonary tuberculosis according to risk factors. Int J Tuberc Lung Dis, 2019, 23(6):698-706. doi: 10.5588/ijtld.18.0541. doi: 10.5588/ijtld.18.0541 pmid: 31315702
[32]	张静, 李杰玉. 老年人肺结核临床特点研究. 中国实用医药, 2015, 10(3):160-170.
[33]	Zhao JN, Zhang XX, He XC, et al. Multidrug-Resistant Tuberculosis in Patients with Chronic Obstructive Pulmonary Disease in China. PLoS One, 2015, 10(8):e0135205. doi: 10.1371/journal.pone.0135205. doi: 10.1371/journal.pone.0135205
[34]	Yakar HI, Gunen H, Pehlivan E, et al. The role of tuberculosis in COPD. Int J Chron Obstruct Pulmon Dis, 2017, 12: 323-329. doi: 10.2147/COPD.S116086. doi: 10.2147/COPD.S116086 URL
[35]	Allwood BW, Rigby J, Griffith-Richards S, et al. Histologically confirmed tuberculosis-associated obstructive pulmonary disease. Int J TubercLung Dis, 2019, 23(5):552-554. doi: 10.5588/ijtld.18.0722. doi: 10.5588/ijtld.18.0722
[36]	Allwood BW, Maasdorp E, Kim GJ, et al. Transition from Restrictive to Obstructive Lung Function Impairment During Treatment and Follow-Up of Active Tuberculosis. Int J Chron Obstruct Pulmon Dis, 2020, 15:1039-1047. doi: 10.2147/COPD.S219731. doi: 10.2147/COPD.S219731 URL
[37]	Bromberg PA, Robin ED. Abnormalities of lung function in tuberculosis. Bibl Tuberc, 1963, 17:1-27.
[38]	Sarkar M, Srinivasa, Madabhavi I, et al. Tuberculosis associated chronic obstructive pulmonary disease. Clin Respir J, 2017, 11(3):285-295. doi: 10.1111/crj.12621. doi: 10.1111/crj.12621 pmid: 28268242
[39]	Plit ML, Anderson R, Van Rensburg CE, et al. Influence of antimicrobial chemotherapy on spirometric parameters and pro-inflammatory indices in severe pulmonary tuberculosis. Eur Respir J, 1998, 12(2): 351-356. doi: 10.1183/09031936.98.12020351. doi: 10.1183/09031936.98.12020351 pmid: 9727784
[40]	Chung KP, Chen JY, Lee CH, et al. Trends and predictors of changes in pulmonary function after treatment for pulmonary tuberculosis. Clinics (Sao Paulo), 2011, 66(4):549-556. doi: 10.1590/s1807-59322011000400005. doi: 10.1590/s1807-59322011000400005 URL
[41]	Jo YS, Park JH, Lee JK, et al. Risk factors for pulmonary arterial hypertension in patients with tuberculosis-destroyed lungs and their clinical characteristics compared with patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis, 2017, 12:2433-2443. doi: 10.2147/COPD.S136304. doi: 10.2147/COPD.S136304 URL
[42]	Agusti A, Fabbri LM, Singh D, et al. Inhaled corticosteroids in COPD: friend or foe? Eur Respir J, 2018, 52(6):1801219. doi: 10.1183/13993003.01219-2018. doi: 10.1183/13993003.01219-2018 URL
[43]	刘跃, 姜晓艳.糖尿病肺病. 中华内科杂志, 2012, 51(1): 67-69. doi: 10.3760/cma.j.issn.0578-1426.2012.01.020. doi: 10.3760/cma.j.issn.0578-1426.2012.01.020
[44]	Xin HN, Cao X, Zhang H, et al. Protective efficacy of 6-week regimen for latent tuberculosis infection treatment in rural China: 5-year follow-up of a randomised controlled trial. Eur Respir J, 2021[2022-02-10]. doi: 10.1183/13993003.02359-2021. Online ahead of print. doi: 10.1183/13993003.02359-2021. Online ahead of print